mortality/aging
• reduced median (93 vs. 102 weeks) and maximum lifespan
|
• accelerated onset of age-related phenotypes
|
adipose tissue
• at 104 weeks without a decrease in the dermal layer thickness
|
• reduced total fat mass at 24 months
• reduced fat depot size at 104 weeks
|
• at 104 weeks
|
• reduced subscapular fat pad weight at 24, but not 15, months
|
• at 24, but not 15, months
|
• at 24, but not 15, months
|
cellular
aneuploidy
(
J:194926
)
• in mouse embryonic fibroblasts
|
• incidence of premature chromosome separation in mouse embryonic fibroblasts is increased compared to in wild-type
|
• age-related
|
skeleton
N |
• mice exhibit normal bone mineral density
|
• lordokyphosis at 89 weeks without evidence of osteoporosis
|
muscle
• at 15 months in the gastrocnemius, paraspinal and abdominal muscles
• however, muscle fiber diameter at 3 months
|
• pronounced by 65 weeks
|
neoplasm
• mice treated with DMBA exhibit larger lung tumor size compared with wild-type mice
• however, tumor incidence and multiplicity are normal
|
homeostasis/metabolism
• reduced at 65 weeks
|
growth/size/body
• at 24, but not 15, months
|
cardiovascular system
N |
• unlike Bub1btm1Jvd homozygotes, mice do not exhibit cardiac arrhythmias
|
integument
• at 104 weeks without a decrease in the dermal layer thickness
|
vision/eye
behavior/neurological
• reduced at 65 weeks
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
mosaic variegated aneuploidy syndrome 1 | DOID:0080141 |
OMIM:257300 |
J:194926 |